(Drug Information Association: Horsham, Pennsylvania) -- The Drug Information Association (DIA) will host its eighth annual DIA Conference for Contemporary Pharmacovigilance and Risk Management Strategies, January 11–15 in Washington, D.C. This annual event addresses current complexities and controversies in pharmacovigilance and risk management throughout all phases of development and marketed use.

Among this year’s topics are:

• U.S. Food and Drug Administration and European Medicines Agency risk management initiatives
• Generating and assessing critical safety data during development
• Compliance with global clinical safety and postmarketing pharmacovigilance regulatory requirements
• Relationship between compliance and quality in safety-related processes and procedures
• New approaches in risk management, risk communication, labeling, and packaging to optimize medical product benefits while minimizing preventable harm

“The field of medical product safety continues to grow in complexity, with both clinical trial safety and postmarketing pharmacovigilance becoming ever more critical in the development and ongoing evaluation of safe use of marketed medical products,” explains program chair Stephen A. Goldman, M.D. “The inherent limitations of premarketing testing and constant focus on the risks associated with medical product use have fostered new thinking and methods for monitoring the evolving safety profiles of marketed products throughout their life cycle. Further, risk management requires ongoing refinement in order to enhance its applicability and value to public health.”

For further information, visit www.diahome.org/DIAHOME/Education/FindEducationOffering.aspx?productID=17943&eventType=meeting.